Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 <sup>+</sup> Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic LeukemiaJean‐Baptiste Robin, Marie Balsat, Gabrielle Roth-Guépin et al.|Journal of Clinical Oncology|2024Cited by 33
Genetic alterations and MRD refine risk assessment for <i>KMT2A</i>-rearranged B-cell precursor ALL in adults: a GRAALL studyRathana Kim, Emmanuelle Clappier, Hugo Bergugnat et al.|Blood|2023Cited by 29
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemiaYves Chalandon, Hervé Dombret, Philippe Rousselot et al.|Blood|2024Cited by 28
Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2Nicolas Boissel, Hervé Dombret, Françoise Huguet et al.|Blood|2021Cited by 23
Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B StudyNicolas Boissel, Hervé Dombret, Françoise Huguet et al.|Blood|2022Cited by 23